The White House has ordered the National Institutes of Health (NIH) to study "regret" among transgender people who have ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force ...

With its remote endovascular procedure system currently under review at the FDA, Microbot Medical has put forward positive ...

After more than 13 years at Johnson & Johnson, including most recently serving as new ventures lead for Italy within J&J ...

“Leadership in the agency’s been decapitated, and I think that was somewhat deliberate,” Janet Woodcock, M.D., former acting ...

In late March, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced 10,000 layoffs across ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...